#Paris #France #BOTOX #Allergan Aesthetics #TrenibotulinumtoxinE

Allergan Aesthetics Showcases New Advances at IMCAS 2026

Allergan Aesthetics, part of AbbVie, is set to unveil groundbreaking data on its facial aesthetics offerings at the 2026 International Master Course on Aging Science (IMCAS) conference, scheduled for January 29-31 in Paris. This event will feature nine e-posters that collectively highlight the company's commitment to advancing aesthetics medicine through innovative research and new product development.

Comprehensive Data on Facial Injectables

The presentation at IMCAS will include detailed findings on Allergan Aesthetics' diverse portfolio, which features first-in-class products like TrenibotulinumtoxinE, a botulinum neurotoxin serotype E designed to provide rapid results with a shorter duration of effect, particularly aimed at treating glabellar lines. This innovative product is currently under regulatory review, with its safety and efficacy demonstrated in pooled Phase 3 studies.

In addition to TrenibotulinumtoxinE, the presentation will cover key data on BOTOX® Cosmetic and its long-term benefits for patient satisfaction when used for upper facial lines. A commitment to presenting comprehensive safety data further reinforces Allergan Aesthetics’ dedication to maintaining high standards of patient care.

John Maltman, Vice President of Global Aesthetics Medical Affairs at Allergan Aesthetics, stated, "Our focus on scientifically driven innovation is paving the way for the future of aesthetic medicine. With this new research showcased at IMCAS 2026, we aim to address patient concerns while providing healthcare providers with valuable insights into both established and emerging treatment options across neurotoxin, biostimulatory, and hyaluronic acid (HA) filler modalities."

Poster Presentations Highlighting Patient Satisfaction

The highlighted e-posters will not only present efficacy and safety data but will also emphasize patient satisfaction outcomes post-treatment. The analysis includes a specific focus on providing natural-looking results and reinforcing the psychological benefits associated with aesthetic treatments. Data from multiple Phase 4 studies regarding OnabotulinumtoxinA will shine a light on the motivating factors for patients opting for long-term facial rejuvenation treatments.

The e-posters scheduled for display at IMCAS cover various aspects, including:

• - Age-Related Efficacy Outcomes after treatment with TrenibotulinumtoxinE
• - Treatment satisfaction and natural-looking outcomes differentiated by participant sex for OnabotulinumtoxinA
• - Insights into the effectiveness of hyaluronic acid injectables in the periorbital region, particularly focusing on different demographic groups.

Educational Symposia and Expert Panels

Moreover, Allergan Aesthetics will host two educational symposia featuring global experts discussing evolving trends in aesthetic medicine. These expert-led sessions will delve into the next generation of toxins and patient-focused strategies utilizing the AA Signature™ approach, which integrates Allergan's product offerings with comprehensive training and services aimed at delivering personalized treatment experiences.

Engaging Experience at the Conference

Delegates attending IMCAS will have the opportunity to interact with Allergan Aesthetics’ representatives at their booth, where they can engage in an interactive product injection experience. This platform not only allows attendees to learn about the advanced portfolio and treatment options but also fosters meaningful discussions around the science behind these innovations.

Allergan Aesthetics’ commitment to evidence-based aesthetics medicine, paved with continuous research and development, is designed to meet the needs of patients seeking personalized and effective aesthetic solutions. As the company strides forward at IMCAS 2026, the future of aesthetics appears brighter than ever.